RxDoctor Payments Data

Matthew Miller, MD

Adult Reconstructive Orthopaedic Surgery · Stanford, CANPI 1093901886

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (50.8%), education and travel and lodging — rather than concentrated in one kind of arrangement. Zimmer Biomet accounts for 99.4% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2024 at $36,222 and has fallen 64.4% since, to $12,908 in 2025.

$92,933in general payments, 2019–2025

Across 104 payments — averaging $893.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Zimmer Biomet$92K
  • DJO, LLC$275
  • Portola Pharmaceuticals, LLC$207
  • Heron Therapeutics, Inc.$51
  • Convatec Inc.$25
  • Vertex$22
  • plus $13 from 1 others

What the payments were for

  • Consulting fees$47,17551%
  • Travel & lodging$5,8596%
  • Food & beverage$2,0602%
  • Education$37,84041%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$92,933 in reported general payments places this provider in the 75th percentile of 136 adult reconstructive orthopaedic surgery providers in California.

See all adult reconstructive orthopaedic surgery providers in California

Medicare billing

Part B allowed, 2024
$538,936
Medicare patients
601
Services billed
1,202

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Celecoxib25$591

Paid to pharmacies, not to this prescriber.

Other adult reconstructive orthopaedic surgery in Stanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →